Pharmacology/Pharmaceutical Industry | Page 23 of 172 | Links Medicus Content Curation & Alerts in Medicine

Cohort Study: Effectiveness of Pfizer, Moderna, and AstraZeneca vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting.

1 Jul, 2022 | 11:37h | UTC

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study – BMJ Medicine

Commentary on Twitter

🎉 Read our latest research article comparing the effectiveness of three #COVID vaccines against severe COVID outcomes. ▶️ https://t.co/uaQNgnDrrV #BMJMedicine #MedTwitter #openaccess pic.twitter.com/4oeG5d0j80

— BMJMedicine (@BMJMedicine) June 16, 2022

RCT: Oxaliplatin (3 months vs. 6 months) with 6 months of Fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer.

1 Jul, 2022 | 10:59h | UTC

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07 – Journal of Clinical Oncology

Cohort Study: Pfizer vaccine effectiveness against omicron in children 5 to 11 years of age.

30 Jun, 2022 | 11:21h | UTC

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age – New England Journal of Medicine

Secondary analysis of a RCT: Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.

30 Jun, 2022 | 10:58h | UTC

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes – Circulation

Original Study: Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine

RCT: A 2-week interruption in methotrexate treatment doubles the antibody response to a COVID-19 booster vaccine.

29 Jun, 2022 | 12:10h | UTC

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial – The Lancet Respiratory Medicine

News Releases:

Interrupting the treatment of vulnerable people on immune-suppressing medicines, doubles their antibody response to COVID-19 booster vaccination – University of Nottingham

Interrupting immune-suppressing treatment can boost COVID vaccine response – Imperial College London

Commentaries:

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment – The Lancet Respiratory Medicine

Covid-19: Pausing immune suppressing drugs enhances antibody response to boosters, study shows – The BMJ

Commentary on Twitter

NEW Research—2-week interruption of methotrexate treatment for people w/ immune-mediated inflammatory diseases = enhanced boosting of antibody responses after #COVID19 vaccination

From Prof Abhishek Abhishek & colleagues https://t.co/y14pUEaB5X pic.twitter.com/pLvaXjJzoz

— The Lancet Respiratory Medicine (@LancetRespirMed) June 28, 2022

Perspective | Fast-evolving COVID variants complicate vaccine updates.

29 Jun, 2022 | 12:01h | UTC

Fast-evolving COVID variants complicate vaccine updates – Nature

An analysis of SARS-CoV-2 vaccine reactogenicity: variation by type, dose, and history, severity, and recency of prior SARS-CoV-2 infection.

29 Jun, 2022 | 11:52h | UTC

An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection – Open Forum Infectious Diseases

Network meta-analysis: Dipeptidyl peptidase-4 inhibitors increase the risk of cholecystitis in patients with type 2 diabetes.

29 Jun, 2022 | 11:24h | UTC

Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials – The BMJ

Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside.

29 Jun, 2022 | 11:01h | UTC

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside – Drugs

Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.

29 Jun, 2022 | 10:59h | UTC

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review – Drugs

RCT: Two-day vs. seven-day course of levofloxacin in acute COPD exacerbation.

28 Jun, 2022 | 11:19h | UTC

Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial – Therapeutic Advances in Respiratory Disease

Commentary: Antibiotics in COPD Exacerbations – 2 days vs 7 days – RebelEM

Epilepsy: what are the best medications?

28 Jun, 2022 | 11:14h | UTC

Epilepsy: what are the best medications? – Evidently Cochrane

Original Study: Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data – Cochrane Library

Cohort Study: Association of receipt of the fourth BNT162b2 dose with omicron infection and COVID-19 hospitalizations among residents of long-term care facilities.

28 Jun, 2022 | 11:08h | UTC

Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities – JAMA Internal Medicine

Commentary: Fourth Dose of BNT162b2 Prevents Severe COVID-19 in Nursing Home Residents – HealthDay

Commentary on Twitter

Cohort study found that vaccination with a fourth BNT162b2 dose vs 3 doses given 4 months or earlier, was associated with lower risk of hospitalizations by 64-67% and deaths by 72%, among residents of long-term care facilities during massive Omicron surge. https://t.co/LTZ4umgSDh

— JAMA Internal Medicine (@JAMAInternalMed) June 23, 2022

Drug treatment algorithm and recommendations for the management of rheumatoid arthritis.

28 Jun, 2022 | 11:05h | UTC

Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication – Modern Rheumatology

M-A: Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable.

28 Jun, 2022 | 10:50h | UTC

Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter

https://twitter.com/TheLancetPsych/status/1540353436377554947

Systematic Review: Antibiotics for uncomplicated diverticulitis.

27 Jun, 2022 | 11:56h | UTC

Antibiotics for uncomplicated diverticulitis – Cochrane Library

Summary: Antibiotics for uncomplicated diverticulitis – Cochrane Library

Efficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link to abstract – $ for full-text)

The WSES/SICG/ACOI/SICUT/AcEMC/SIFIPAC guidelines for diagnosis and treatment of acute left colonic diverticulitis in the elderly – World Journal of Emergency Surgery

Diagnosis and Management of Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians – Annals of Internal Medicine

Colonoscopy for Diagnostic Evaluation and Interventions to Prevent Recurrence After Acute Left-Sided Colonic Diverticulitis: A Clinical Guideline From the American College of Physicians – Annals of Internal Medicine

Changing Paradigms in the Management of Acute Uncomplicated Diverticulitis – Scandinavian Journal of Surgery

Elective surgical management of diverticulitis – Current Problems in Surgery

Management of Colonic Diverticulitis – Agency for Healthcare Research and Quality

2020 update of the WSES guidelines for the management of acute colonic diverticulitis in the emergency setting – World Journal of Emergency Surgery

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis – Diseases of the Colon & Rectum

Commentary on Twitter

The benefits of antibiotics in diverticulitis are uncertain with respect to complications, emergency✂️, recurrence, elective colonic resections&long‐term complications. This may be because diverticulitis is❌an infectious disorder, but an inflammatory onehttps://t.co/0HmAllw5Af

— John Damianos, M.D. (@john_damianosMD) June 26, 2022

Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.

27 Jun, 2022 | 11:51h | UTC

Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada – JAMA Network Open

Commentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)

[Press Release – not published yet]: RCT: Sanofi-GSK report its vaccine targeted against ancestral and Beta strains had an overall efficacy of 72% against the Omicron variant.

27 Jun, 2022 | 11:52h | UTC

Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine – Sanofi

Commentaries: Bivalent COVID Vax Gets Phase III Win Against Omicron, Companies Say — Sanofi, GSK boast of 72% efficacy against Omicron variant – MedPage Today (free registration required)

Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide.

27 Jun, 2022 | 11:46h | UTC

News Release: Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide – Imperial College London

Original Study: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study – The Lancet Infectious Diseases

Commentaries:

The global impact of disproportionate vaccination coverage on COVID-19 mortality – The Lancet Infectious Diseases

Covid-19 vaccines prevented nearly 20 million deaths in a year, study estimates – STAT

COVID-19 vaccines saved an estimated 20 million lives in 1 year – CIDRAP

COVID-19 Vaccines Saved Almost 20 Million Lives in a Year, Modelling Study Estimates – Health Policy Watch

Commentary on Twitter (thread – click for more)

🆕 @TheLancetInfDis
In the 1st year of Covid vaccinations, ~20 million deaths were prevented worldwide (data from 185 countries)
Another ~600,000 lives would have been saved if the @WHO 40% target been achievedhttps://t.co/BWig83xlnN @azraghani @imperialcollege @MRC_Outbreak pic.twitter.com/lF8biBJIlK

— Eric Topol (@EricTopol) June 23, 2022

Cohort Study: The risk of stroke is substantially higher in the first year of initiation of oral contraceptives or hormone replacement therapy.

27 Jun, 2022 | 11:44h | UTC

Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk – Stroke (link to abstract – $ for full-text)

Commentary: Flash of Greater Stroke Risk at Initiation of Oral Contraceptives — Risk with hormone replacement therapy lingers in the long run, though – MedPage Today (free frustration required)

Phase 2a RCT: Vaccine efficacy in adults in a respiratory syncytial virus challenge study.

27 Jun, 2022 | 11:21h | UTC

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study -New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Challenge Study Shows Efficacy of RSV Vaccine in Healthy Adults – HealthDay

Commentary on Twitter

A human challenge model was used to assess the safety and immunogenicity of an RSV prefusion F protein-based vaccine against RSV infection. The vaccine construct has advanced to further clinical testing.https://t.co/KKfqzCyyGF pic.twitter.com/H7i7F8KLmv

— NEJM (@NEJM) June 22, 2022

Analysis of 7 RCTs: Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis.

27 Jun, 2022 | 10:56h | UTC

Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis – The Journal of Allergy and Clinical Immunology: In Practice

Commentary: Treatment Reduces, Exterminates Hospitalizations in Adults With Moderate to Severe AD – Consultant360

Commentary on Twitter

In Current Issue! #Dupilumab Treatment Reduces #Hospitalizations in #Adults With #Moderate– #to– #Severe #Atopic #Dermatitis https://t.co/eYqy95FADb pic.twitter.com/pRaVh9tw4S

— JACI In Practice (@JACIInPractice) May 10, 2022